Vancouver, British Columbia – March 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today it has initiated a research collaboration with the laboratory of Dr. Michael R. Elliott of the University of Rochester School of Medicine and Dentistry.
Dr. Elliott’s lab is testing the capacity of Qu Biologics’ SSIs to activate macrophages for enhanced activity in vivo using novel preclinical mouse models and state-of-the-art immunologic assays systems. Dr. Elliott is a recognized expert in macrophage biology and function, having published in Nature, the Journal of Cell Biology and the Journal of Immunology. Dr. Elliott’s lab is part of the David H. Smith Center for Vaccine Biology and Immunology at the University of Rochester in upstate New York. Dr. Elliott has developed advanced mouse models to assess macrophage activation and efficacy in vivo.
Qu Biologics’ Chief Scientific Officer Dr. David Mullins commented, “Qu is pleased to be working with the University of Rochester to evaluate the effects of our proprietary SSIs in Dr. Elliott’s highly-informative and unique mouse model system.” Dr. Mullins added, “Qu has demonstrated that SSIs induce effective immune responses in preclinical models of cancer and inflammatory bowel disease, and Dr. Elliott’s work will advance our detailed understanding of the role of a specific cell – the macrophage – in SSIs’ biologic activity.”
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases, such as inflammatory bowel disease. The company is currently recruiting participants for a placebo-controlled, randomized clinical trial in Crohn’s disease and a clinical trial in non-small cell lung cancer, and is initiating a trial in ulcerative colitis in Q2 2015.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Qu Biologics Inc.
Phone: 604.734.1450 ext.41491
Email: julie@qubiologics.com
———————————————
Help employers find you! Check out all the jobs and post your resume.
